Importantly, AFP has also been shown to serve as a crucial prognostic biomarker for patients with HCC undergoing immunotherapy, highlighting its multifaceted roles in HCC biology and clinical management [104]. This evidence concerns the gene AFP and hepatocellular carcinoma.